Fucoxanthin, Chlorella, and Dihydromyricetin: Evidence Behind Liver-Wellness Ingredients

Direct answer: Fucoxanthin, chlorella, and dihydromyricetin have plausible metabolic or antioxidant mechanisms, but their human evidence differs sharply. Chlorella has several small trials and low-certainty meta-analyses; fucoxanthin has limited, formulation-specific trials; isolated dihydromyricetin remains supported mainly by cell and animal research. None of this proves that a multi-ingredient liver supplement treats fatty liver disease, prevents alcohol injury, or produces the same results as a studied ingredient.

Quick Takeaways

• Fucoxanthin is a marine carotenoid. Human trials are limited, and several positive studies used a mixture rather than fucoxanthin alone.
• Chlorella has been studied in people with metabolic or liver conditions, but trial quality, geography, co-interventions, and product differences limit confidence.
• Dihydromyricetin, commonly shortened to DHM, has extensive preclinical alcohol-related research but very little direct human evidence using isolated DHM.
• A study of one ingredient cannot establish the effect of a finished proprietary blend, especially when individual ingredient amounts are not disclosed.
• Liver enzymes are clinical signals, not a home scorecard. Normal or improved numbers do not automatically prove that liver fat, fibrosis, or disease risk has changed.
• Supplements do not neutralize alcohol, replace metabolic care, or make an unhealthy pattern safe.

Why These Three Ingredients Are Often Grouped Together

Fucoxanthin, chlorella, and dihydromyricetin come from different biological sources and are not interchangeable. Fucoxanthin is a carotenoid found in brown seaweed and certain microalgae. Chlorella is a freshwater green microalga used as a food or supplement. Dihydromyricetin is a flavonoid associated with plants such as *Hovenia dulcis* and *Ampelopsis grossedentata*.

They appear together in liver-wellness conversations because laboratory and animal studies connect them with overlapping themes: oxidative stress, lipid handling, inflammatory signaling, and alcohol-related stress. Those themes are biologically interesting, but a shared mechanism diagram is not the same as a shared clinical outcome.

For consumers, the most useful question is not whether an ingredient has an antioxidant mechanism. It is whether the specific form, amount, population, comparison group, and outcome in a human study match the product being considered.

Evidence Snapshot

Fucoxanthin: A Marine Carotenoid With Limited Clinical Translation

What Fucoxanthin Is

Fucoxanthin is a xanthophyll carotenoid that contributes to the brown or olive color of many marine algae. After ingestion, it is metabolized into compounds including fucoxanthinol. Laboratory research has explored effects on lipid metabolism, glucose regulation, inflammation, and energy expenditure.

These pathways have produced confident marketing language, but human research remains much smaller than the preclinical literature.

What Human Trials Have Reported

A frequently cited 2010 randomized trial enrolled 151 obese, nondiabetic premenopausal women with or without nonalcoholic fatty liver. The intervention was Xanthigen, a combination of brown-seaweed extract containing fucoxanthin and pomegranate seed oil. Some groups experienced changes in weight, liver fat, liver enzymes, and resting energy expenditure over 16 weeks.

That trial is relevant but cannot answer what isolated fucoxanthin would do. It also studied a defined population and a specific combination, not every seaweed extract or every liver-wellness formula.

An eight-week Japanese trial assigned 60 adults to fucoxanthin-enriched akamoku oil providing 0, 1, or 2 mg of fucoxanthin daily. Researchers did not find significant changes in visceral fat or resting energy expenditure, although they reported a signal for lower HbA1c in the 2 mg group. A later 12-week trial in 37 overweight women found that a microalgae extract providing 4.4 mg of fucoxanthin did not add weight or fat loss beyond a structured diet and exercise program, although some secondary outcomes differed.

The responsible conclusion is mixed, not negative or positive in absolute terms. Fucoxanthin has human research, but outcomes vary and cannot be generalized across doses, sources, combinations, and populations.

Why Absorption and Formulation Matter

Carotenoids are lipophilic. Food matrix, accompanying fat, extraction method, stability, and delivery technology can affect how much reaches circulation. A product may use microencapsulation or another delivery system, but a technology claim still needs product-specific data before it can be linked to a clinical benefit.

Chlorella: More Human Data, Still Low Certainty

What Chlorella Is

Chlorella is a nutrient-containing microalga. Commercial preparations vary by species, strain, cultivation, cell-wall processing, extraction, and nutrient composition. A whole-cell chlorella powder is not automatically equivalent to a branded extract.

What Liver-Enzyme Research Shows

A 2021 systematic review and meta-analysis pooled seven randomized trials. Chlorella supplementation was associated with lower AST overall, while results for ALT and alkaline phosphatase were less consistent and appeared context-dependent. The authors called for larger studies across more conditions.

A newer 2026 review focused on people with fatty liver disease and included seven trials with 375 participants. It reported changes in weight, fasting glucose, selected lipids, inflammatory markers, AST, and alkaline phosphatase. However, every included trial was conducted in Iran, and the authors rated the certainty of evidence as very low because of risk of bias and limited generalizability.

One individual eight-week trial illustrates another limitation. Participants with fatty liver received chlorella plus vitamin E, while the control group received vitamin E plus placebo. Because both groups received vitamin E and several outcomes changed in both groups, the study does not isolate every effect consumers may attribute to chlorella.

What Liver Enzymes Do and Do Not Tell You

AST and ALT can rise for many reasons, and a person can have significant liver disease with modest or even normal enzyme values. A reduction in one laboratory marker does not necessarily prove reduced liver fat, lower fibrosis risk, or a change in long-term clinical outcomes.

Someone with abnormal liver tests needs a clinical assessment, not a supplement experiment based on a single marker. Medication effects, alcohol exposure, viral hepatitis, metabolic disease, gallbladder problems, muscle injury, and other causes may need to be considered.

Dihydromyricetin: Strong Preclinical Interest, Weak Direct Human Evidence

What DHM Is

Dihydromyricetin is a flavonoid often discussed in relation to alcohol metabolism, oxidative stress, neurotransmission, and liver protection. Cell and animal studies have investigated ethanol-related inflammation, steatosis, mitochondrial function, and behavioral effects.

The gap appears when the question changes from “Can DHM affect a pathway in a model?” to “Does an isolated oral DHM supplement improve meaningful outcomes in people?”

What the Human Evidence Actually Tests

A 2026 systematic review of alcohol-attributed conditions found extensive preclinical research but only two small clinical studies. Those human studies used *Hovenia dulcis* extracts, not isolated DHM. The review concluded that clinical evidence was limited and that well-designed trials of standardized DHM are needed.

This distinction matters because a plant extract may contain multiple compounds. Even if DHM is present, a result from the entire extract cannot be assigned to DHM alone. It also cannot establish that another formulation with a different amount, delivery system, or accompanying ingredients will perform similarly.

DHM Does Not Make Alcohol Safe

No supplement has been shown to prevent alcohol overdose, eliminate impairment, protect every organ from ethanol, or make driving safe. DHM should not be used to justify drinking more, delay emergency care, or replace medical treatment for alcohol use disorder or liver disease.

The practical conclusion is simple: less alcohol means less risk, and only time allows the body to clear alcohol.

The Ingredient-to-Formula Evidence Gap

Moving from a paper to a finished product requires several checks:

1. Identity: Is the study ingredient the same species, extract, form, and standardization?
2. Amount: Does the product disclose an amount comparable with the research?
3. Delivery: Is the ingredient processed or delivered in the same way?
4. Population: Were participants similar to the person considering the product?
5. Outcome: Did the study measure symptoms, laboratory markers, imaging, or clinical events?
6. Formula: Was the complete finished blend tested, or only one component?

A mechanistic study can support biological plausibility. A randomized trial of an isolated ingredient can support an ingredient-level conclusion. Neither automatically proves the performance of a multi-ingredient finished product.

Where Ultra Liver Cleanse Fits

Ultra Liver Cleanse uses two proprietary blends. The current Supplement Facts list a 446 mg Hepato-Regene Complex containing fucoxanthin, Clovinol clove-bud extract, Yaeyama chlorella extract, and dihydromyricetin. A separate 354 mg Lipo-Lytic Complex lists rice-bran policosanol, bergamot extract, and tiliroside from rose hip.

The individual amounts are not disclosed. That means consumers cannot map the finished formula directly to the amounts used in the fucoxanthin, chlorella, or DHM literature. Delivery descriptions such as microencapsulation or cyclodextrin inclusion may be relevant to formulation, but they are not proof of a clinical outcome.

The product's appropriate position is daily nutrition support for normal liver function and lipid metabolism, alongside lower alcohol exposure, a sustainable dietary pattern, physical activity, sleep, weight and metabolic care when relevant, and appropriate clinical testing. It is not a fatty-liver treatment, a detoxification procedure, or a hangover antidote. The broader priorities are explained in the liver and metabolic wellness supplement guide.

Safety Questions to Ask Before Use

Do You Have Liver or Gallbladder Disease?

Do not self-treat abnormal liver tests, jaundice, persistent right-upper-abdominal pain, dark urine, pale stools, unexplained itching, swelling, or confusion. These findings need prompt medical assessment. People with diagnosed liver or gallbladder disease should ask their clinician about every supplement and botanical they use.

Do You Take Prescription Medicines?

Multi-ingredient supplements can create interaction questions that a single-ingredient paper does not cover. Bring the complete label to a pharmacist or clinician, especially if you use anticoagulants, antiplatelet drugs, diabetes medicines, cholesterol medicines, immunosuppressants, or medicines with liver warnings.

Are You Pregnant, Breastfeeding, or Preparing for Surgery?

Human safety information for several concentrated extracts is limited in pregnancy and breastfeeding. Elective surgery also changes the risk calculation for botanicals and supplements. Ask the relevant clinician rather than assuming that a natural source means universal safety.

Are You Using Multiple “Detox” or Weight-Loss Products?

Stacking products increases exposure and makes it difficult to identify the cause of an adverse effect. It can also duplicate ingredients that are not obvious from front-label marketing. Use one complete supplement list when discussing safety with a healthcare professional.

A Consumer Checklist for Reading Ingredient Evidence

• Identify the exact ingredient form used in the paper.
• Note whether the evidence is from cells, animals, observational studies, or randomized human trials.
• Check participant characteristics and study duration.
• Separate primary outcomes from exploratory secondary findings.
• Look for a placebo or appropriate comparison group.
• Check whether the intervention was a combination.
• Compare research amounts only when the product discloses individual amounts.
• Treat enzyme changes as clinical data that require context, not as a guarantee of organ repair.
• Ask whether the finished product itself has been studied.
• Avoid any claim that a supplement cancels alcohol, poor diet, or a diagnosed condition.

FAQs

References

• Abidov M, Ramazanov Z, Seifulla R, Grachev S. The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. *Diabetes, Obesity and Metabolism*. 2010.
• Mikami N, et al. Reduction of HbA1c levels by fucoxanthin-enriched akamoku oil: a randomized controlled trial. *British Journal of Nutrition*. 2017.
• Kreider RB, et al. Effects of a microalgae extract containing fucoxanthin during a weight-management intervention. 2024.
• Yarmohammadi S, et al. Effect of Chlorella vulgaris on liver function biomarkers: a systematic review and meta-analysis. *Clinical Nutrition Research*. 2021.
• Jafari A, et al. Chlorella vulgaris supplementation in people with fatty liver disease: a GRADE-assessed systematic review. *BMC Cardiovascular Disorders*. 2026.
• Ebrahimi-Mameghani M, et al. The effect of Chlorella vulgaris supplementation on liver enzymes, serum glucose, and lipid profile. 2014.
• Zakhari S, et al. Therapeutic effects of dihydromyricetin on wholly alcohol-attributed conditions: a systematic review. *Nutrients*. 2026.
• National Institutes of Health Office of Dietary Supplements. Dietary Supplements for Weight Loss.

This article is for educational purposes and does not diagnose, treat, cure, or prevent disease. Dietary supplements do not replace medical evaluation, prescribed treatment, lower-risk alcohol decisions, a balanced diet, physical activity, or appropriate liver and metabolic testing.